Calidi Biotherapeutics Inc. (CLDI)
AMEX AMEX Primary Summary
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Calidi Biotherapeutics, Inc. (CLDI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / May 17, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics Inc. (NYSE American:CLDI) and Unusual Machines Inc. (NYSE American:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 18, at 7 p.m. Eastern Time (ET).
Calidi Biotherapeutics Inc. (CLDI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Calidi Biotherapeutics Inc. ever had a stock split?
Calidi Biotherapeutics Inc. Profile
| AMEX Exchange | US Country |
Overview
Calidi Biotherapeutics, Inc. is a pioneering firm situated in the forefront of the immuno-oncology landscape, focusing on the clinical development of innovative allogeneic stem cell-based platforms. These platforms are designed to enhance and deliver oncolytic viruses directly to cancer patients, an approach that signifies a novel pathway in cancer treatment. Operating from its headquarters in San Diego, California, the company is immersed in the challenge of addressing some of the most formidable cancers by harnessing the power of stem cells in synergy with oncolytic viruses.
Products and Services
Calidi Biotherapeutics’ product pipeline is a testament to its innovative approach towards combating cancer, with several products in different stages of clinical and preclinical trials:
- CLD-101 (Phase 1b Clinical Trial): Targeting the treatment of high-grade glioma, CLD-101 is under phase 1b clinical trial, demonstrating Calidi's dedication to addressing one of the most challenging brain cancers.
- CLD-101 (Phase 1 Clinical Trial): Also focused on high-grade glioma, another form of CLD-101 is in phase 1 clinical trial, specifically aiming at recurrent high-grade glioma, offering hope for patients facing relapse.
- CLD-201 (Preclinical Trial): Aiming at the treatment of advanced solid tumors, including triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma, CLD-201 represents Calidi's venture into a wider range of difficult-to-treat cancers, showing the scalability of their technology.
- CLD-400 (Preclinical Trial): With a focus on lung cancer and metastatic solid tumors, CLD-400 broadens the company’s pipeline, indicating the versatility of its platforms to potentially benefit a vast array of cancer patients.
In addition, Calidi Biotherapeutics is spearheading the development of cutting-edge platforms like NeuroNova and SuperNova, which are central to the company's strategy of revolutionizing cancer treatment through biotechnological innovation. These platforms underpin the company's product pipeline and showcase its commitment to groundbreaking research in immuno-oncology.
